Terms and Conditions for the Invetx website, outlining the use of the website, intellectual property rights, and limitations of liability.

At Invetx, we bring the best of biopharma to animal health. 

We are building the world’s premier animal health biotechnology innovation platform for protein-based therapeutics. 

Working closely with best-in-class biotechnology companies, major investors and an extensive network of industry experts, we are focused on guiding the development of an exciting portfolio of therapies and technologies to deliver the future of animal care.

Our network includes experts in both animal and human health, veterinary scientists and clinicians. Our vision is of a global animal health industry that fully leverages biopharma technologies to deliver dramatically improved health outcomes for pets and farm animal populations.

You will also be able to hear from us on Twitter at @invetx.

Tekla Capital Management

WuXi Biologics

Casdin Capital

AbCellera

Anterra Capital

Novo Holdings

Eight Roads Ventures

Google Ventures

F-Prime Capital

Invetx

Come hear our senior vice president of CMC and manufacturing, Dr. Krishnan Sampath, who will be the featured speaker on the upcoming webinar “Road Map for Drug Product Development and Manufacturing of Biologics.” Sponsored by the International Pharmaceutical Federation (FIP), the webinar will be held on February 29th, 2024 at 3 pm CET (9 am EST/6 am PST). Read more details and register here: https://lnkd.in/dMxFr-8h.
#veterinaryantibodies #animalhealth #biologicsdrugdevelopment

"Wishing a very merry holiday season to all of our collaborators and supporters from the team at Invetx!

Recent market research showed that a majority of pet owners and veterinarians would switch to a longer-acting, higher-priced therapeutic to treat chronic osteoarthritis pain in dogs and cats for greater convenience and compliance. This study validates Invetx’s innovative patented half-life extension platform, which extends dosing intervals by at least two to three months. The technology is being applied to our portfolio of monoclonal antibody (mAb) therapeutics for chronic conditions in cats and dogs.

The study, which included approximately 2,000 companion animal veterinarians and pet owners, also showed a significantly higher incidence of osteoarthritis/chronic pain in dogs and cats than previously thought (30-40% v. 20 %). Read more here. https://lnkd.in/gsvp7_Nc

Congratulations to Krishnan Sampath, PhD, our senior vice president of CMC and manufacturing, and co-author of the recent publication “Roadmap for Drug Product Development and Manufacturing of Biologics” in the Journal of Pharmaceutical Sciences (November 07, 2023, https://lnkd.in/gA3sTZJW). The paper establishes a unified framework and roadmap for successful biologics drug development, from early development to manufacturing and commercialization. 

At Invetx, Dr. Sampath is applying his deep expertise to help advance our portfolio of differentiated and best-in-class mAb therapeutics for cats and dogs at an affordable cost. His team has established a 3rd party manufacturing network for veterinary mAbs under FDA/EMA as well as USDA jurisdiction, successfully progressed one product candidate to GMP production and introduced advanced technology platforms to further reduce cost-of-goods.

We are pleased to announce the completion of our novel canine and feline half-life extension technology platform, which significantly extends duration of monoclonal antibody treatment effect, making chronic diseases more manageable and providing better value for dog and cat owners. Learn more  at https://lnkd.in/gdwfqvn3.

 
Invetx is pleased to announce that Dr. Marcus Remmers, a life sciences executive with deep animal health and veterinary biologics expertise, has joined our board of directors. Currently a partner at Novo Holdings and a member of the Global Future Council at the World Economic Forum, Dr. Remmers previously held several senior positions at Merial (now Boehringer Ingelheim Animal Health) including VP, global head of biologics R&D and VP, global head of pharma R&D. He also recently served as chief technology officer at DSM, a global animal health, nutrition and bioscience company. #animalhealth #veterinarybiotherapeutics


COM:INVETX

Invetx, Inc.

Analysis Not Available